Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns “Buy” Rating from Chardan Capital
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at Chardan Capital in a report issued on Friday,Benzinga reports. They presently have a $300.00 price target on the biopharmaceutical company’s stock. Chardan Capital’s price target would indicate a potential upside of 5.88% from the stock’s current price. A […]
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at Chardan Capital in a report issued on Friday,Benzinga reports. They presently have a $300.00 price target on the biopharmaceutical company’s stock. Chardan Capital’s price target would indicate a potential upside of 5.88% from the stock’s current price. A […]
